Liminatus Pharma, Inc Class A Common Stock
Quarterly Financials
| Values in thousands | 2025-09-30 | 2025-03-31 |
|---|---|---|
Revenue | $0 | $0 |
Gross Profit | ||
EBITDA | -1,803 | |
EBIT | -1,804 | |
Net Income | -1,823 | |
Net Change In Cash | 0 | 0 |
Free Cash Flow | -613 | 0 |
Cash | 724 | 804 |
Basic Shares | 27,007 | 27,064 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 |
|---|---|---|
Revenue | $0 | $0 |
EBITDA | -1,089 | -2,709 |
Net Income | -1,226 | -2,928 |
Net Change In Cash | 0 | 0 |
Free Cash Flow | -3,345 | -869 |
Cash | 434 | 5,048 |
Basic Shares | 8,012 | 34,428 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-09-30 | -$0.07 |
2025-06-30 | $0.004 |
2025-03-31 | -$0.12 |
2024-12-31 | -$0.12 |
